This study is testing a new targeted drug called JAB-21822 for Chinese patients with advanced colorectal cancer that has a specific genetic change called KRAS G12C. The drug is combined with standard second-line chemotherapy and another cancer drug (bevacizumab) after initial tre…
Phase: PHASE1 • Sponsor: Jian Li • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC